Table 1.
Full cohort n(%) | Died within 30 days n (%) | Survived n (%) | Odds ratio | 95% CI | P | |
---|---|---|---|---|---|---|
Total | 62 | 8(100) | 54(100) | |||
Gender (male) | 40 (64.5) | 6 (75.0) | 34 (63.0) | 0.512 | ||
Age, median (years) | 69 (range; 1–92) | 76 (range; 52–86) | 69 (range; 1–92) | 0.126 | ||
Duration from admission to bacteremia, median (days) | 17 (range; 3–142) | 33(range; 9–142) | 16(range; 3–86) | 0.089 | ||
Duration of antibiotic therapy from diagnosis of PVC-BSI, median (days) | 16 (range; 5–100) | 17(range; 7–46) | 16(range; 3–100) | 0.737 | ||
Time from catheter insertion to bacteremia, median (days) | 6 (range; 2–15) | 7 (range; 2–9) | 7 (range; 3–15) | 0.526 | ||
Unknown | 26 (41.9) | 2 (25.0) | 24 (44.4) | 0.42 | 0.08–2.25 | 0.298 |
< 3 days | 4 (11.1) | 2 (25.0) | 2 (3.7) | 8.67 | 1.03–73.25 | 0.022 |
4–7 days | 19 (52.8) | 1(16.7) | 18 (66.7) | 0.29 | 0.03–2.50 | 0.232 |
> 8 days | 13 (36.1) | 3(50.0) | 10 (30.0) | 2.64 | 0.54–12.91 | 0.218 |
Causative microorganism (including duplicate polymicrobials) | ||||||
Gram-positive microorganisms | 47(58.0) | 7(77.8) | 40(54.8) | 2.45 | 0.28–21.72 | 0.408 |
S.aureus | 14(17.3) | 5(62.5) | 9(16.7) | 8.33 | 1.68–41.29 | 0.004 |
MSSA | 10(71.4) | 3(37.5) | 7(12.7) | 4.03 | 0.78–20.70 | 0.078 |
MRSA | 4(28.6) | 2(25.0) | 2(3.7) | 8.67 | 1.03–73.25 | 0.022 |
CNS | 21(25.9) | 2(25.0) | 16(29.6) | 0.79 | 0.14–4.35 | 0.788 |
Bacillus spp. | 6(7.4) | 0 | 6(11.1) | 0.44 | 0.02–8.53 | 0.576 |
Enterococcus spp. | 6(7.4) | 0 | 6(11.1) | 0.44 | 0.02–8.53 | 0.576 |
Gram-negative microorganisms | 30(35.8) | 2(22.2) | 28(38.4) | 0.31 | 0.06–1.67 | 0.156 |
Enterobacter spp. | 9(11.1) | 0 | 6(11.1) | 0.44 | 0.02–8.53 | 0.576 |
Klebsiella spp. | 5(6.2) | 1(12.5) | 4(7.4) | 1.79 | 0.17–18.35 | 0.621 |
Pseudomonus spp. | 4(4.9) | 1(12.5) | 3(5.6) | 2.43 | 0.22–26.69 | 0.455 |
Acinetobacter spp. | 4(4.9) | 0 | 4(7.4) | 0.66 | 0.03–13.40 | 0.785 |
Serratia spp. | 4(4.9) | 0 | 4(7.4) | 0.66 | 0.03–13.40 | 0.785 |
E.coli | 3(3.7) | 0 | 3(5.6) | 0.87 | 0.04–18.29 | 0.926 |
Citrobacter spp. | 1(1.2) | 0 | 1(1.9) | 2.10 | 0.08–55.84 | 0.651 |
Candida spp. | 5(6.2) | 0(0.0) | 5(6.8) | 0.53 | 0.03–10.48 | 0.671 |
Polymicrobial | 16(25.8) | 1(12.5) | 15(27.8) | 0.37 | 0.04–3.28 | 0.357 |
Underlying diseases (including duplicate) | ||||||
Malignancy | 33 (53.2) | 4(50.0) | 26(48.1) | 1.08 | 0.24–4.76 | 0.922 |
Hypertension | 14 (22.6) | 0 | 14 | 0.16 | 0.01–0.03 | 0.172 |
Diabetes mellitus | 11 (17.7) | 0 | 11 | 0.22 | 0.01–4.15 | 0.274 |
Cerebral infarction | 7 (11.3) | 2(25.0) | 5(9.3) | 3.27 | 0.52–20.69 | 0.189 |
Orthopedic disorder | 3 (4.8) | 0 | 3 (5.6) | 0.87 | 0.04–18.29 | 0.926 |
Department | ||||||
Surgery | 35 (56.5) | 3(37.5) | 32(59.3) | 0.41 | 0.09–1.91 | 0.247 |
Internal medicine | 21 (33.9) | 5(62.5) | 16(29.6) | 3.96 | 0.84–18.57 | 0.067 |
Obstetrics and Gynecology | 5 (8.1) | 0 | 5 (9.3) | 0.53 | 0.03–10.48 | 0.672 |
Pediatrics | 1 (1.6) | 0 | 1 (1.9) | 2.10 | 0.08–55.84 | 0.651 |
Place of insertion | ||||||
Arm | 48 (77.4) | 7 (87.5) | 41 (75.9) | 2.22 | 0.25–19.76 | 0.465 |
Foot | 3 (4.8) | 1(12.5) | 2 (3.7) | 3.71 | 0.30–46.48 | 0.279 |
Unknown | 11 (17.7) | 0 | 11 (20.4) | 0.22 | 0.01–4.15 | 0.274 |
Complication | ||||||
Suppurative thrombophlebitis | 18 (29.0) | 3(37.5) | 15(27.8) | 1.56 | 0.33–7.35 | 0.572 |
Bacterial cellulitis | 3 (4.8) | 2 (25.0) | 1 (1.8) | 17.67 | 1.39–225.05 | 0.004 |
Osteomyelitis | 2 (3.2) | 0 | 2 (3.7) | 1.24 | 0.05–28.02 | 0.894 |
Abbreviations: S. aureus, Staphylococcus aureus; MSSA, Methicillin-sensitive S. aureus; MRSA, Methicillin-resistant S. aureus; CNS, coagulase-negative Staphylococcus; P. aeruginosa, Pseudomonus aeruginosa; E. coli, Escherichia coli
Footnote: Some of the patients included in our study had multiple diseases. When we calculated the incidence of each underlying disease, we included the patients with multiple underlying diseases in all relevant calculations, so some patients were counted more than once